Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Journal of Nucleic Acids|September 18, 2010
The Role of PCNA Posttranslational Modifications in Translesion SynthesisMontaser Shaheen, Ilanchezhian Shanmugam, Robert Hromas
Blood|March 29, 2011
Synthetic lethality: exploiting the addiction of cancer to DNA repairMontaser Shaheen, Christopher Allen, Jac A Nickoloff, et al.
Pharmacological Research|July 11, 2017
Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistanceBhargavi Pulluri, Abhijeet Kumar, Montaser Shaheen, et al.
Genetica|March 24, 2010
Metnase/SETMAR: a domesticated primate transposase that enhances DNA repair, replication, and decatenationMontaser Shaheen, Elizabeth Williamson, Jac Nickoloff, et al.
American Journal of Clinical Oncology|June 1, 2004
Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) studyMontaser Shaheen, Michael J Stender, John W McClean, et al.
Investigational New Drugs|September 8, 2010
Cytotoxic activity of the titanium alkoxide (OPy)(2)Ti(4AP)(2) against cancer colony forming cellsElizabeth A Williamson, Timothy J Boyle, Rebecca Raymond, et al.
The Oncologist|October 18, 2017
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label StudyGeorge A Fisher, Edward M Wolin, Nilani Liyanage, et al.
Plos One|April 25, 2009
Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cellsJustin Wray, Elizabeth A Williamson, Melanie Royce, et al.
Cancer Treatment Reviews|July 10, 2017
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their managementMario Sznol, Michael A Postow, Marianne J Davies, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 17, 2018
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDYGeorge A Fisher, Edward M Wolin, Nilani Liyanage, et al.
Pageof 4